Drug Approval | February 25, 2023
Pfizer’s Elranatamab receives FDA and EMA filing acceptance
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
Innate to receive $5M milestone payment from AstraZeneca
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures
Subscribe To Our Newsletter & Stay Updated
